Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor that has been widely known as a pain mediator involved in various pain states. Evidence indicates that ET-1 sensitizes transient receptor potential cation channel, subfamily A, member 1 (TRPA1) in vivo. But the molecular mechanisms still remain unknown. We aim to explore whether ET-1 sensitizes TRPA1 in primary sensory neurons and the molecular mechanisms. Ca 2þ imaging, immunostaining, electrophysiology, animal behavioral assay combined with pharmacological experiments were performed. ET-1 sensitized TRPA1-mediated Ca 2þ responses in human embryonic kidney (HEK)293 cells as well as in cultured native mouse dorsal root ganglion (DRG) neurons. ET-1 also sensitized TRPA1 channel currents. ET-1 sensitized TRPA1 activated by endogenous agonist H 2 O 2 . ET A receptor (ET A R) colocalized with TRPA1 in DRG neurons. ET-1-induced TRPA1 sensitization in vivo was mediated via ET A R and protein kinase A (PKA) pathway in HEK293 cells and DRG neurons. Pharmacological blocking of ET A R, PKA, and TRPA1 significantly attenuated ET-1-induced mechanical hyperalgesia in mice. Our results suggest that TRPA1 acts as a molecular target for ET-1, and sensitization of TRPA1 through ET A R-PKA pathway contributes to ET-1-induced mechanical hyperalgesia. Pharmacological targeting of TRPA1 and ET A R-PKA pathway may provide effective strategies to alleviate pain conditions associated with ET-1.
Introduction
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide that has been implicated in the pathogenesis of tissue inflammation and pain. 1 Injection of ET-1 induced overt pain-like behavior and thermal and mechanical allodynia in animals. [2] [3] [4] In humans, ET-1 injection produced severe pain and prolonged, touch-evoked allodynia. 5 ET-1 exerts its effects mainly via acting on ET A and ET B receptors (ET A R and ET B R), both of which are G protein-coupled receptors. 1 ET A Rs are abundantly expressed in primary sensory neurons, whereas ET B R are found exclusively in satellite glial cells. 6, 7 Extensive studies have been carried out to elucidate the mechanisms underlying ET-1-induced pain responses. ET-1 can induce hyperpolarizing shifts in voltage-dependent activation of TTX-R Na þ channels. 8 ET-1 also potentiates TRPV1 channel via ET A R-mediated protein kinase C (PKC) signaling in both expression system and sensory neurons. 6 Transient receptor potential cation channel, subfamily A, member 1 (TRPA1) is a nonselective cation ion channel mainly distributed in sensory neurons where it functions as a molecular detector to sense a variety of noxious stimuli. TRPA1 can be activated by a wide variety of endogenous and exogenous substances that elicit pain and irritation. 9 Activation of TRPA1 depolarizes nociceptors and contributes to the perception of noxious stimuli. 9 In addition, TRPA1 channel activity can be sensitized by inflammatory mediators, including bradykinin, trypsin, and nerve growth factor (NGF). [10] [11] [12] TRPA1 can be sensitized via protein kinase A (PKA) and phospholipase C (PLC) pathways. 10, [13] [14] [15] ET-1 can potentiate cinnamaldehyde (a TRPA1 agonist)-induced nociception. 16 ET-1-induced mechanical allodynia is inhibited by specific antagonists against TRPA1 and ET A R in vivo, suggesting a possible interaction between ET A R and TRPA1 in mediating pain responses. 17 However, little is known about whether ET-1 sensitizes TRPA1 in primary sensory neurons and the detailed mechanisms.
Here, we investigated whether ET-1 sensitizes TRPA1 channel expressed in heterologous expression system and in cultured mouse primary sensory neurons. We further studied the molecular mechanisms underlying ET-1's effect on TRPA1. Lastly, we examined the contribution of ET A R-PKA pathway and TRPA1 in ET-1-induced nocifensive response. Our results suggest that ET-1 sensitizes TRPA1 via ET A R and PKA signaling pathway both in vitro and in vivo, and this pathway contributes to ET-1-induced mechanical hyperalgesia.
Material and Methods

Animals
Male C57BL/6 mice (from Laboratory of Animal Research Center, Zhejiang Chinese Medical University, Hangzhou, China and Charles River Laboratories, Wilmington, MA, USA), six to eight weeks old, were used in this study. Trpa1 -/-mice were a gift from David Julius (University of California, San Francisco, CA, USA). The mice were housed 5 per cage on a 12 h light/dark cycle with controlled temperature. Food and water were provided ad libitum. This study was carried out in accordance with the guidelines of National Institutes of Health guide for the care and use of laboratory animals and approved by the Animal Ethics Committee of Zhejiang Chinese Medical University.
Chemicals
Dimethyl sulfoxide (DMSO), HQ, ionomycin, capsaicin, and mustard oil (MO) were obtained from SigmaAldrich (St. Louis, MO, USA). HC-030031, ET-1, H89, BQ-123, BQ-788, edelfosine, forskolin, and bisindolylmaleimide (BIM) were purchased from Tocris (Minneapolis, MN, USA).
Cell culture
Human embryonic kidney (HEK)293 cells (ATCC, CRL-1573) were cultured in Dulbecco's modified Eagle's medium (Lonza, Belgium) supplemented with 10% fetal bovine serum (Lonza, Belgium), 2 mM L-glutamine, 100 units/ml penicillin, and 100 lg/ml streptomycin. Cells were transfected by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to manufacturer's instruction. Human TRPA1 (hTRPA1) is a gift from Professor David Julius (University of California, San Francisco), and ET A R is purchased from OriGene (Rockville, MD).
Adult mouse dorsal root ganglia (DRGs) were dissociated using 0.28 Wu¨nsch units/ml Liberase Blendzyme 1 (Roche Diagnostics, Mannheim, Germany) as described previously. 18 Neurons were cultured in Neurobasal-A medium (Invitrogen, Grand Island, NY) with B-27 supplement, 0.5 mM glutamine, and 50 ng/ml NGF (Calbiochem, La Jolla, CA) on an 8-well chambered coverglass coated with poly-D-lysine (Sigma, St. Louis, MO) and mouse laminin (Invitrogen, Carlsbad, CA, USA).
Immunofluorescence and confocal imaging
Mice were euthanized by CO 2 . Bilateral L3-5 DRGs were collected and immersed immediately in 4% paraformaldehyde overnight at 4 C. Then, DRGs were transferred to 15% and 30% sucrose for dehydration. Mouse DRGs were then frozen in frozen tissue matrix (OCT) and cut by cryostat in 8-lm sections. For immunostaining, the sections were first blocked with 1% BSA plus 10% donkey serum for 2 h at room temperature. The sections were then incubated overnight at 4 C with primary antibody against TRPA1 (1:200, Alomone Labs, Jerusalem, Israel) and ET A R (1:200, Abcam, Carlsbad, CA, USA). After washout, corresponding secondary antibodies (1:1000, Abcam, Carlsbad, CA, USA) were used for staining. Fluorescence signals were detected by Nikon A1R laser scanning confocal microscope (Nikon, Japan) and analyzed by ImageJ software. For quantification of immunofluorescent staining, two images were randomly selected per mouse tissue, and three mice were included in the present study. 
Patch-clamp recordings
Recordings were carried out with borosilicate glass pipettes with initial series resistance of 2 to 4 MX after loading the pipette solution. Currents were filtered at 2.3 kHz and digitized at 100ls intervals using an EPC-10 amplifier and PatchMaster acquisition software (HEKA, Germany). Perforated whole-cell hTRPA1 currents in HEK293 cells were recorded by patch-clamp recordings with a pipette solution containing (in mM) 140 CsAsp, 2 MgCl 2 , 10 HEPES, and 10 Ethylene glycol-bis(2-aminoethylether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA) (pH 7.4, adjusted with CsOH), with $30 pM of amphotericin B added. The perfusion solution contained (in mM) 140 NaCl, 4 KCl, 2 EGTA, 2 MgCl 2 , 10 HEPES, and 8 glucose (pH 7.4, adjusted with NaOH).
Animal behavioral assay
Mechanical hyperalgesia was examined by von Frey hair test as described before. 19, 20 Briefly, mice were habituated for 30 min to the wire mesh surface before testing. Paw withdrawal thresholds (PWTs) were determined using a series of von Frey filaments (0.008-4.00 g) pressed against the plantar surface of the hind paw in ascending order beginning with the finest fiber following standard procedures. The minimum force (g) that caused the mouse to withdraw its hind paw away from the filament was considered as the withdrawal threshold. For each paw, a von Frey hair was applied 5 times at 10-s intervals. The threshold was determined when paw withdrawal was observed in more than three of five applications. ET-1 (20 ng/paw, dissolved in phosphate-buffered saline) was injected into the hind paw of mice using 1-ml syringe and 30-gauge needle in a volume of 20 ll. HC-030031 (10 mg/paw), H89 (5 mg/paw), and BQ-123 (1 mg/paw) was coinjected with ET-1, and the behavioral test was carried out thereafter at 0, 0.5, and 2.5 h after the injection. All behavioral tests were performed by an experimenter blinded to experimental conditions.
Statistics
Student's t-test was used for comparison of data between two groups. One-way or two-way analysis of variance followed by Tukey post hoc test was used for comparison of ! 3 groups. Comparison is considered significantly different if the p value is less than 0.05. Data in bar graphs are expressed as means AE SE.
Results
ET-1 sensitizes hTRPA1 channel expressed in heterologous expression system
We transiently expressed hTRPA1 and ET A R together in HEK293 cells. To examine whether ET-1 sensitizes TRPA1, we measured its effects on Ca 2þ responses to TRPA1 agonist MO in HEK293 cells. We tested the effects of 100 nM ET-1 in our in vitro experiments, which is a commonly used concentration in other studies and falls within the in vivo ET-1 concentration range. 6, 7, 21 Pretreatment of HEK293 cells for 2 min with ET-1 (100 nM) significantly increased the magnitude of Ca 2þ responses to MO (5 mM) compared to pretreatment with vehicle (0.1% DMSO), indicating sensitization effect of ET-1 (Figure 1 We proceeded to examine the mechanisms underlying ET-1-induced sensitization of TRPA1 in HEK293 cells. We used percent of ionomycin response, in which cell responses to MO were normalized to ionomycin, to compare Ca 2þ responses among different groups. ET A R couples to PLC and PKA pathway, respectively. 22, 23 Since TRPA1 can be sensitized by PLC and PKA, we therefore examined the contributions of these two pathways to ET-1-induced sensitization of TRPA1 in HEK293 cells. ET A R-specific antagonist BQ-123 (10 mM), but not ET B R-specific antagonist BQ-788 (5 mM), at effective concentration, significantly reduced ET-1-induced sensitization of Ca 2þ responses to MO in HEK293 cells. [24] [25] [26] [27] H89 (10 mM), a PKA antagonist, significantly reduced the sensitization, whereas BIM (100 nM), a PKC antagonist, had no effect ( Figure 1(c) ). In line with this observation, pretreating HEK293 cells with forskolin (15 mM), a PKA agonist, sensitizes the Ca 2þ responses to MO in HEK293 cells, mimicking the effect of ET-1. On the contrary, the PLC-specific antagonist edelfosine, at effective concentration (10 mM), had no effect on ET-1-induced TRPA1 sensitization. 28 We further studied the effects of ET-1 on TRPA1/ ET A R-expressing HEK293 cells via whole-cell patchclamp recording. TRPA1 channel current was recorded under Ca 2þ -free extracellular solution to avoid channel inactivation as in our previous study. 29 It was observed that 5 mM of MO induced small TRPA1 currents showing typical outward rectification property (Figure 2 
ET-1 sensitizes TRPA1 channel in mouse primary sensory neurons
It is reported that ET A Rs are mainly expressed in DRG neurons. 6, 7 We therefore performed double immunostaining experiments using specific antibody against ET A R in conjunction with antibody against TRPA1. We found that a large population (over 80%) of TRPA1 positive neurons was labeled for ET A R (Figure 3 ). Out of 78 ET A R-positive neurons, 69 were stained positive for TRPA1 (6 sections obtained from 3 mice). This high percentage of coexpression suggests a possible functional interaction between TRPA1 and ET A R in mouse DRG neurons.
We began to examine the effects of ET-1 on primary sensory neurons. Cultured mouse dorsal root ganglion (DRG) neurons were loaded with Fura-2 for Ca 2þ imaging. Application of ET-1 (100 nM) did not induce strong Ca 2þ signals in mouse DRG neurons as in HEK293 cells (Figure 4(a) and (b) ). The summarized percent of responding neurons to ET-1 application is not significantly different from vehicle-treated group (3. 3 AE 1.5% vs. 2.0 AE 0.9%, p > 0.05). We set to examine whether ET-1 was capable of sensitizing TRPA1 channel in DRG neurons. We used low concentrations of MO (5 mM) and capsaicin (10 nM) to activate TRPA1 and TRPV1 subsequently. In control group (vehicle-treated), 5 mM MO barely induced any Ca 2þ signal, whereas subsequent application of 10 nM capsaicin induced only small Ca 2þ signal in DRG neurons (Figure 4 (a) and (b)). When DRG neurons were pretreated with ET-1 (100 nM), however, larger Ca 2þ responses were recorded with low concentration of MO (5 mM) (Figure 4 in neurons derived from Trpa1 knockout (Trpa1 -/-) mouse (Figure 4(c) , (e), and (f)). In contrast, the sensitizing effect of ET-1 on capsaicin-induced Ca 2þ signal remained unaltered in Trpa1 -/-neurons (Figure 4(c) , (e), and (f)). ET A R antagonist BQ-123 (10 mM) and PKA antagonist H89 (10 mM) largely eliminated ET-1-induced sensitization on TRPA1 (Figure 4(d) , (e), and (f)). PLC antagonist edelfosine (10 mM) had no effect on ET-1- induced sensitization of TRPA (Figure 4 (e) and (f)). Therefore, the above results demonstrated that ET-1 sensitizes TRPA1 in DRG neurons via ET A R and PKA pathway.
TRPA1 can be activated by a variety of endogenous agonists that activate TRPA1 to produce pain signals. We examined whether ET-1 sensitizes TRPA1 activated by hydrogen peroxide (H 2 O 2 ), a well-established endogenous agonist for TRPA1. 30 In HEK293 cells expressing ET A R and TRPA1, ET-1 (100 nM) treatment significant increased the magnitude of Ca 2þ responses to H 2 O 2 (1 mM) compared with vehicle-treated group (control) (Figure 5(a) and (b) ). ET-1 (100 nM) treatment also significantly increased magnitude of Ca 2þ responses to 
TRPA1 mediates ET-1-induced mechanical hyperalgesia in vivo
We examined the contribution of TRPA1 in ET-1-induced nocifensive behavior in vivo. Mice injected with ET-1 into hind paw (20 ng/paw) showed obvious signs of mechanical hyperalgesia compared with mice receiving vehicle injection only, measured 0.5 and 2.5 h after injection ( Figure 6 ). HC-030031 (10 mg/paw), the TRPA1 antagonist, significantly reduced the mechanical hyperalgesia induced by ET-1. PKA antagonist H89 (5 mg/paw) and ET A R antagonist BQ-123 (1 mg/paw) both significantly attenuated the mechanical hyperalgesia induced by ET-1 ( Figure 6 ). Injection of these antagonists alone in the same dosage as above did not produce any effects on PWTs compared with vehicle (control) group (Table 1) . In all, these results demonstrated that ET-1 elicited mechanical hyperalgesia through TRPA1 via ET A R and PKA pathway.
Discussion
In the present study, we found that ET-1 sensitizes TRPA1 via ET A R and PKA-mediated signaling pathway both in vitro and in vivo. Our findings are based upon the following observations: First, ET-1 sensitizes TRPA1 channel in HEK293 cells via ET A R and PKAmediated pathway. Second, ET-1 does not produce robust Ca 2þ signals in DRG neurons but sensitizes MO-activated TRPA1 channel activity. Third, ET-1 sensitizes TRPA1 channel activated by endogenous agonist H 2 O 2 . Last, blocking TRPA1, ET A R, and PKA all significantly alleviated ET-1-induced mechanical hyperalgesia.
ET A Rs are widely expressed in small and medium-tolarge diameter neurons and, in particular, in TRPV1-expressing small sensory neurons, whereas ET B Rs are mainly found in satellite glial cells but not in sensory neurons. 6, 7 TRPA1 are distributed in sensory neurons that also express TRPV1. 31 Previous studies revealed ET A R coexpressed largely with TRPV1 in mouse DRG neurons. 6 This suggests that TRPA1 is likely to coexpress with ET A R in sensory neurons. Our immunostaining results demonstrated that a large population (over 80%) of TRPA1-positive DRG neurons also express ET A R. The high percentage of coexpression suggests a possible functional interaction between TRPA1 and ET A R in DRG neurons.
ET A R couples through G aq/11 to PLCb and the release of inositol trisphosphate (IP 3 ) to induce intracellular Ca 2þ release. 23, 32 In HEK293 cells which are overexpressed with ET A R, we found that ET-1 application elicited large Ca 2þ responses, which gradually subsided in the continued presence of ET-1. This suggests that ET-1 binds with ET A R and initiates Ca 2þ signals which is likely mediated via PLCb-IP 3 pathway in HEK293 cells. In contrast, ET-1 did not elicit obvious Ca 2þ signals in native DRG neurons in our study. It is reported that ET-1 only induced quite small intracellular Ca 2þ transients in mouse DRG neurons, but its effect on satellite nonneuronal cells is much larger. 33 Recently, one study reported that only a small proportion (approximate 3%) of DRG neurons respond to ET-1 application in Ca 2þ imaging. 7 This responding rate to ET-1 is similar with our findings. But unfortunately, no comparisons between ET-1-responding and vehicleresponding rate were included in that study. In the present study and our previous publication, we found that even vehicle application produces small and random Ca 2þ transients in DRG neurons during Ca 2þ imaging. 18 Therefore, it still remains to be investigated whether ET-1 can truly induce reliable and robust Ca 2þ signals in mouse DRG neurons.
ET A R also couples to PKA signaling pathway. 22, 34 ET-1 induces intracellular cAMP level increase in HEK293 cells expressing ET A R but not ET B R, suggesting ET A R couples with PKA signaling in HEK293 cells.
6
TRPA1 can be sensitized by inflammatory mediators, such as bradykinin and tryptase, via PKA and PLC pathways. 10, 13, 15, 35 Further study identified the amino acid residues involved in PKA-mediated phosphorylation and sensitization of TRPA1. 14 We examined the contribution of these two pathways to ET-1-induced sensitization of TRPA1. PWT: paw withdrawal threshold; NS: no significance. BQ-123 (1 mg/paw), H89 (5 mg/paw), or HC-030031 (10 mg/paw) and corresponding vehicle (1% dimethyl sulfoxide in phosphate-buffered saline, control) were administered intraplantarly into the hind paws of mice. PWTs were measured before and 0.5 and 2.5 h after drug/vehicle treatment.
TRPA1. These results demonstrate that ET-1-induced sensitization of TRPA1 in vitro requires ET A R-mediated PKA signaling pathway.
ET-1 potentiates TRPV1 channel, which underlies ET-1-induced nocifensive behavior. 36 However, ET-1-induced nociceptive response is not completely inhibited in Trpv1 -/-mice or by TRPV1 antagonist, suggesting other mechanisms are involved as well. 3, 37 In addition to TRPV1, TRPA1 is involved in ET-1-induced mechanical hypersensitivity. 17 We found that ET-1 induced mechanical hyperalgesia is significantly reduced by TRPA1-specific antagonist HC-030031, as well as by PKA and ET A R antagonists. These findings suggest that TRPA1 is a molecular target of ET-1 in mediating nociceptive responses.
Oxidative stress occurs during many pathophysiological conditions including inflammation and tissue injury, which produces a variety of highly reactive oxygen species (ROS) including H 2 O 2 , lipid peroxidation products, like 4-hydroxy-2-nonenal and Oxidized 1-palmitoyl-2-arachidonoyl-sn-glycerol-3-phosphatidylcholine (OxPAPC). 38 These ROS products act as endogenous TRPA1 agonists and are involved in many inflammatory and neuropathic pain conditions. 20, 39 ET-1 is generated during tissue inflammation and damage and involved in pathogenesis of pain. 1 The concentration of ET-1 (100 nM) we tested falls well within ET-1's endogenous concentration range reported. 21 Thus, our findings suggest that ET-1-induced TRPA1 sensitization is likely to occur in pathological conditions.
In addition to causing pain, ET-1 is also known to cause pruritus. 7 This property is shared with many other stimulators of peripheral sensory neurons. Pain and itch sensations are activated by excitation of separate populations of peripheral sensory neurons, the nociceptors, and the pruriceptors, respectively. 40 Recent studies demonstrated that nociceptors and pruriceptors engage spinal circuits that, depending on stimulus strength, duration, and lateral spread of inputs, control whether itch or pain is transduced, or whether itch is suppressed (by scratching, for example). 40, 41 It is possible that high local concentrations of ET-1 may favor pain since widespread nociceptor activation is known to suppress itch sensations, while lower local concentrations favor itch sensation. The role of TRPA1 in ET-1-induced pruritus remains controversial. While TRPA1 inhibitors were found to increase ET-1-induced scratching responses in mice immediately after injection, a study in Trpa1 -/-mice observed that ET-1 induced scratching was attenuated. 7, 42 Additional studies, potentially using more selective inhibitors and longer observation time, may be necessary to clarify the role of TRPA1 in ET-1-induced pruritus.
It has been reported that ET-1 can potentiate TRPA1 agonist cinnamaldehyde-induced nociception in vivo. 16 Further studies demonstrated that ET-1-induced mechanical allodynia is inhibited by specific antagonists against TRPA1 or ET A R in vivo, suggesting a possible interaction between ET A R and TRPA1 in mediating pain responses. 17 However, little is known about whether ET-1 acts on TRPA1 in primary sensory neurons and the detailed molecular mechanisms. Our findings showed for the first time that ET A R couples with TRPA1 in primary sensory neurons, which provide another molecular mechanism for explaining ET-1-induced pain response. Our results demonstrate that TRPA1 acts as a novel molecular target for ET-1 and sensitization of TRPA1 through ET A R-PKA pathway contributes to ET-1-induced mechanical hyperalgesia. Targeting of TRPA1 and ET A R-PKA pathway may offer effective strategies to alleviate pain conditions related with ET-1.
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